Post Content
#ASH25: Lilly’s Jaypirca matches Imbruvica in Phase 3 early blood cancer trial
Eli Lilly has shown that Jaypirca is as good as, if not better than, Johnson & Johnson and AbbVie’s Imbruvica at shrinking certain types of blood cancer in a late-stage trial that enrolled some first …
#ASH25: Vertex, CRISPR say Casgevy shows promise in younger children
Vertex and CRISPR Therapeutics released first data on Monday showing that their landmark gene therapy Casgevy is effective in kids under 12. Casgevy was approved in 2023 for sickle cell disease and won a label …
Let’s Get Physical: A New Convergence for Electrical Grid Security
The power grid is being attacked online and IRL. Increasingly, regulators and industry experts agree: Security teams need to focus on both cyber and physical threats, together.
Kimberly-Clark inks $40B+ deal for Kenvue
Kimberly-Clark plans to acquire Kenvue in a deal worth about $48.7 billion in enterprise value. The deal, which was announced Monday morning, brings together the makers of Huggies, Tylenol, Kleenex and …
Tylenol maker Kenvue agrees $48.7bn Kimberly-Clark takeover
Facing talc and Tylenol litigation, J&J consumer health spinout Kenvue has agreed to a takeover by consumer goods giant Kimberly-Clark.
UniQure’s Huntington’s gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessing
UniQure’s stock was in freefall Monday morning after the company announced that it might not be able to submit its Huntington’s disease gene therapy for FDA approval on the originally planned timeline. UniQure
AstraZeneca, Lilly, Merck contribute $120M to support manufacturing talent in Virginia
After allocating billions to build facilities in Virginia, AstraZeneca, Eli Lilly and Merck have pledged $40 million each to help develop a manufacturing training centre there. The three drugmakers signed a …
Roche’s Gazyva breaks new ground in lupus
Already approved for kidney damage in lupus, Roche’s Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder.
Tempero halts substance use disorder drug, is ‘assessing strategic alternatives’
A biotech trying to disrupt substance use disorders has paused development of its Phase 2 drug and is looking for alternatives. Tempero Bio, a portfolio company of Aditum Bio, has “temporarily halted advancement of the …